Search

Your search keyword '"CANNON, CHRISTOPHER P."' showing total 6,118 results
Start Over Author "CANNON, CHRISTOPHER P."
6,118 results on '"CANNON, CHRISTOPHER P."'

151. A polygenic risk score predicts atrial fibrillation in cardiovascular disease

Author

Marston, Nicholas A, primary, Garfinkel, Amanda C, additional, Kamanu, Frederick K, additional, Melloni, Giorgio M, additional, Roselli, Carolina, additional, Jarolim, Petr, additional, Berg, David D, additional, Bhatt, Deepak L, additional, Bonaca, Marc P, additional, Cannon, Christopher P, additional, Giugliano, Robert P, additional, O’Donoghue, Michelle L, additional, Raz, Itamar, additional, Scirica, Benjamin M, additional, Braunwald, Eugene, additional, Morrow, David A, additional, Ellinor, Patrick T, additional, Lubitz, Steven A, additional, Sabatine, Marc S, additional, and Ruff, Christian T, additional

Published
2022
Full Text
View/download PDF

152. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Author

Li, Jing‐Wei, primary, Arnott, Clare, additional, Heerspink, Hiddo J. L., additional, MBiostat, Qiang Li, additional, Cannon, Christopher P., additional, Wheeler, David C., additional, Charytan, David M., additional, Barraclough, Jennifer, additional, Figtree, Gemma A., additional, Agarwal, Rajiv, additional, Bakris, George, additional, de Zeeuw, Dick, additional, Greene, Tom, additional, Levin, Adeera, additional, Pollock, Carol, additional, Zhang, Hong, additional, Zinman, Bernard, additional, Mahaffey, Kenneth W., additional, Perkovic, Vlado, additional, Neal, Bruce, additional, and Jardine, Meg J., additional

Published
2022
Full Text
View/download PDF

153. Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel: An Analysis From the TRITON–TIMI 38 Study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38)

Author

Kohli, Payal, Udell, Jacob A., Murphy, Sabina A., Cannon, Christopher P., Antman, Elliott M., Braunwald, Eugene, and Wiviott, Stephen D.

Published
2014
Full Text
View/download PDF

156. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective–2018 Update

Author

Angiolillo, Dominick J., Goodman, Shaun G., Bhatt, Deepak L., Eikelboom, John W., Price, Matthew J., Moliterno, David J., Cannon, Christopher P., Tanguay, Jean-Francois, Granger, Christopher B., Mauri, Laura, Holmes, David R., Gibson, C. Michael, and Faxon, David P.

Published
2018
Full Text
View/download PDF

161. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

Author

Bohula, Erin A., Wiviott, Stephen D., Giugliano, Robert P., Blazing, Michael A., Park, Jeong-Gun, Murphy, Sabina A., White, Jennifer A., Mach, Francois, Van de Werf, Frans, Dalby, Anthony J., White, Harvey D., Tershakovec, Andrew M., Cannon, Christopher P., and Braunwald, Eugene

Published
2017
Full Text
View/download PDF

169. Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.

Author

Arnold, Suzanne V., de Lemos, James A., Zheng, Luke, Rosenson, Robert S., Ballantyne, Christie M., Alam, Shushama, Bhatt, Deepak L., Cannon, Christopher P., and Kosiborod, Mikhail

Subjects
PEOPLE with diabetes, ANGIOTENSIN converting enzyme, CARDIOVASCULAR diseases, ANGIOTENSIN receptors, TYPE 1 diabetes, TYPE 2 diabetes, COHORT analysis
Abstract

Aim: To examine improvement in the use of optimal medical therapy (OMT) for secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) and diabetes. Materials and Methods: Patients with ASCVD (coronary, cerebrovascular, peripheral) and low‐density lipoprotein‐cholesterol of 70 mg/dl or higher were enrolled from December 2016 to July 2018 from 107 US sites/physicians (47% cardiology, 41% primary care, 12% other) and prospectively followed for 2 years (current analysis restricted to subgroup with diabetes). OMT was defined as high‐intensity lipid‐lowering (high‐intensity statin, any statin + ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitor), antithrombotic (antiplatelet or anticoagulant), angiotensin‐converting enzyme‐inhibitor/angiotensin II receptor blocker/angiotensin receptor neprilysin inhibitor (ACE‐I/ARB/ARNI) (excluding glomerular filtration rate [GFR] < 30 ml/min/1.73m2) and sodium‐glucose co‐transporter‐2 inhibitor (SGLT2i)/glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) (excluding GFR < 30 ml/min/1.73m2 and type 1 diabetes). Results: Among 1590 patients with ASCVD and diabetes (96% type 2 diabetes), 58% were on high‐intensity lipid‐lowering therapy at the end of follow‐up, 87% antithrombotic, 71% ACE‐I/ARB/ARNI and 17% SGLT2i/GLP‐1 RA. Overall, 11% of patients received comprehensive OMT, which modestly improved over time (vs. 8% at baseline; P =.002). Patients treated by cardiologists (vs. non‐cardiologists) were more likely to be on high‐intensity lipid lowering, but less likely to be on an SGLT2i/GLP‐1 RA, and thus had lower rates of composite OMT (7.8% vs. 13.7%, P <.001). In a hierarchical multivariable model, older age was associated with lower odds of OMT (OR 0.74 per 10 years, 95% CI 0.60‐0.90), whereas private insurance (OR 1.93, 95% CI 1.32‐2.84) and coronary disease (OR 1.62, 95% CI 1.01‐2.61) were associated with higher odds. The median odds ratio was 1.82 (95% CI 1.03‐7.32), indicating a moderate variability in OMT use, independent of patient factors. Conclusions: We found suboptimal use of secondary prevention in US patients with ASCVD and diabetes, with minimal improvement over time. Further efforts are needed to improve the use of secondary prevention therapies in these patients with high residual risk. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

172. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus

Author

Segar, Matthew W., primary, Kolkailah, Ahmed A., additional, Frederich, Robert, additional, Pong, Annpey, additional, Cannon, Christopher P., additional, Cosentino, Francesco, additional, Dagogo‐Jack, Samuel, additional, McGuire, Darren K., additional, Pratley, Richard E., additional, Liu, Chih‐Chin, additional, Maldonado, Mario, additional, Liu, Jie, additional, Cater, Nilo B., additional, Pandey, Ambarish, additional, and Cherney, David Z. I., additional

Published
2022
Full Text
View/download PDF

173. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis

Author

Li, Chao, primary, Yu, Jie, additional, Hockham, Carinna, additional, Perkovic, Vlado, additional, Neuen, Brendon L., additional, Badve, Sunil V., additional, Houston, Lauren, additional, Lee, Vivian Y. J., additional, Barraclough, Jennifer Y., additional, Fletcher, Robert A., additional, Mahaffey, Kenneth W., additional, Heerspink, Hiddo J. L., additional, Cannon, Christopher P., additional, Neal, Bruce, additional, and Arnott, Clare, additional

Published
2022
Full Text
View/download PDF

175. 481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV

Author

KIM, JOSEPH M., primary, BHATT, DEEPAK L., additional, DAGOGO-JACK, SAMUEL, additional, CHERNEY, DAVID, additional, COSENTINO, FRANCESCO, additional, MCGUIRE, DARREN K., additional, PRATLEY, RICHARD E., additional, LIU, CHIH-CHIN, additional, CATER, NILO B., additional, FREDERICH, ROBERT, additional, MANCUSO, JAMES P., additional, and CANNON, CHRISTOPHER P., additional

Published
2022
Full Text
View/download PDF

177. 172-OR: Eligibility and Utilization of SGLT2i and GLP1-RA in T2D by Cardiovascular and Renal Indications

Author

BLOOD, ALEXANDER, primary, CHANG, LEE-SHING, additional, COLLING, CAITLIN A., additional, GABOVITCH, DANIEL, additional, HAMERSKY, CAROL M., additional, DURDEN, EMILY, additional, HOLT, CASSIE, additional, NOONE, JOSHUA, additional, CANNON, CHRISTOPHER P., additional, WEXLER, DEBORAH J., additional, SCIRICA, BENJAMIN M., additional, WATERMAN, FANTA, additional, STERN, GRETCHEN, additional, and ZELLE, DAVID, additional

Published
2022
Full Text
View/download PDF

181. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI

Author

Costa, Francesco, Valgimigli, Marco, Steg, Philippe Gabriel, Bhatt, Deepak L, Hohnloser, Stefan H, Ten Berg, Jurrien M, Miede, Corinna, Nordaby, Matias, Lip, Gregory Y H, Oldgren, Jonas, Cannon, Christopher P, Costa, Francesco, Valgimigli, Marco, Steg, Philippe Gabriel, Bhatt, Deepak L, Hohnloser, Stefan H, Ten Berg, Jurrien M, Miede, Corinna, Nordaby, Matias, Lip, Gregory Y H, Oldgren, Jonas, and Cannon, Christopher P

Abstract

AIMS Patients with atrial fibrillation undergoing coronary intervention are at higher bleeding risk due to the concomitant need for oral anticoagulation and antiplatelet therapy. The RE-DUAL PCI trial demonstrated better safety with dual antithrombotic therapy (DAT: dabigatran 110 or 150 mg bid, clopidogrel or ticagrelor) compared to triple antithrombotic therapy (TAT: warfarin, clopidogrel or ticagrelor, and aspirin). We explored the impact of baseline bleeding risk based on the PRECISE-DAPT score for decision-making regarding DAT vs. TAT. METHODS AND RESULTS A score ≥25 points qualified high bleeding-risk (HBR). Comparisons were made for the primary safety endpoint ISTH major or clinically relevant non-major bleeding, and the composite efficacy endpoint of death, thromboembolic events, or unplanned revascularization, analyzed by time-to-event analysis. PRECISE-DAPT was available in 2,336/2,725 patients, and 37.9% were HBR. Compared to TAT, DAT with dabigatran 110 mg reduced bleeding risk both in non-HBR (HR 0.42, 95%CI, 0.31-0.57) and HBR (HR 0.70, 95%CI, 0.52-0.94), with a greater magnitude of benefit among non-HBR (Pint=0.02). DAT with dabigatran 150 mg vs. TAT reduced bleeding in non-HBR (HR 0.60, 95%CI, 0.45-0.80), with a trend toward less benefit in HBR patients (HR 0.92, 95%CI, 0.63-1.34, Pint=0.08). Risk of ischaemic events was similar on DAT with dabigatran (both 110 and 150 mg) vs. TAT in non-HBR and HBR patients (Pint=0.45 and Pint=0.56, respectively). CONCLUSIONS PRECISE-DAPT score appeared useful to identify AF patients undergoing PCI at further increased risk of bleeding complications, and may help clinicians identifying the antithrombotic regimen intensity with the best benefit-risk ratio in an individual patient.

Published
2022

186. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin

Author

Corbin, Karen D., Dagogo‐Jack, Samuel, Cannon, Christopher P., Cherney, David Z.I., Cosentino, Francesco, Frederich, Robert, Liu, Jie, Pong, Annpey, Lin, Jianxin, Cater, Nilo B., and Pratley, Richard E.

Subjects
SODIUM-glucose cotransporters, HEPATIC fibrosis, TYPE 2 diabetes, CARDIOVASCULAR diseases, FATTY liver, LIVER enzymes
Abstract

Aim: To conduct a post hoc analysis to explore indices of hepatic steatosis/fibrosis and cardiorenal outcomes in the VERTIS CV study. Materials and Methods: Patients with type 2 diabetes and atherosclerotic cardiovascular (CV) disease were randomized to ertugliflozin or placebo. Liver steatosis and fibrosis were assessed post hoc using the hepatic steatosis index (HSI) and fibrosis‐4 (FIB‐4) index to explore associations with cardiorenal outcomes (ertugliflozin and placebo data pooled, intention‐to‐treat analysis set). Cardiorenal outcomes (major adverse CV events [MACE]; hospitalization for heart failure [HHF]/CV death; CV death; HHF; and a composite kidney outcome) were stratified by baseline HSI and FIB‐4 quartiles (Q1‐Q4). Change in liver indices and enzymes over time were assessed (for ertugliflozin vs. placebo). Results: Amongst 8246 participants, the mean age was 64.4 years, body mass index 32.0 kg/m2, HSI 44.0 and FIB‐4 score 1.34. The hazard ratios (HRs) for MACE, HHF/CV death, CV death, and HHF by FIB‐4 score quartile (Q4 vs. Q1) were 1.48 (95% confidence interval [CI] 1.25, 1.76), 2.0 (95% CI 1.63, 2.51), 1.85 (95% CI 1.45, 2.36), and 2.94 (95% CI 1.98, 4.37), respectively (P < 0.0001 for all). With HSI, the incidence of HHF was higher in Q4 versus Q1 (HR 1.52 [95% CI 1.07, 2.17]; P < 0.05). The kidney composite outcome did not differ across FIB‐4 or HSI quartiles. Liver enzymes and HSI decreased over time with ertugliflozin. Conclusion: In VERTIS CV, higher FIB‐4 score was associated with CV events. HSI correlated with HHF. Neither measure was associated with the composite kidney outcome. Ertugliflozin was associated with a reduction in liver enzymes and HSI. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

196. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

Author

Barraclough, Jennifer Y., primary, Yu, Jie, additional, Figtree, Gemma A., additional, Perkovic, Vlado, additional, Heerspink, Hiddo J. L., additional, Neuen, Brendon L., additional, Cannon, Christopher P., additional, Mahaffey, Kenneth W., additional, Schutte, Aletta E., additional, Neal, Bruce, additional, and Arnott, Clare, additional

Published
2022
Full Text
View/download PDF

197. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial

Author

Charytan, David M., primary, Yu, Jie, additional, Jardine, Meg J., additional, Cannon, Christopher P., additional, Agarwal, Rajiv, additional, Bakris, George, additional, Greene, Tom, additional, Levin, Adeera, additional, Pollock, Carol, additional, Powe, Neil R., additional, Arnott, Clare, additional, and Mahaffey, Kenneth W., additional

Published
2022
Full Text
View/download PDF

198. EFFICACY OF ERTUGLIFLOZIN ON HEART FAILURE HOSPITALIZATION AND HF DEATH ACROSS THE WATCH-DM RISK SCORE: A SECONDARY ANALYSIS OF THE VERTIS CV TRIAL

Author

Segar, Matthew, primary, McGuire, Darren K., additional, Frederich, Robert, additional, Cherney, David Z.I., additional, Cannon, Christopher P., additional, Cosentino, Francesco, additional, Dagogo-Jack, Samuel, additional, Pratley, Richard, additional, Cater, Nilo B., additional, Maldonado, Mario, additional, Emir, Birol, additional, Jeng, Darren, additional, Shi, Harry, additional, and Pandey, Ambarish, additional

Published
2022
Full Text
View/download PDF

199. Cardiovascular Events and Long‐Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE‐IT

Author

Fordyce, Christopher B., primary, Giugliano, Robert P., additional, Cannon, Christopher P., additional, Roe, Matthew T., additional, Sharma, Abhinav, additional, Page, Courtney, additional, White, Jennifer A., additional, Lokhnygina, Yuliya, additional, Braunwald, Eugene, additional, and Blazing, Michael A., additional

Published
2022
Full Text
View/download PDF

200. Reply

Author

Oyama, Kazuma, primary, Giugliano, Robert P., additional, Sabatine, Marc S., additional, Cannon, Christopher P., additional, and Braunwald, Eugene, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results